New class of drugs show anti-tumor activity, research supported by SU2C scientists - Stand Up To Cancer

Give Now

News

New class of drugs show anti-tumor activity, research supported by SU2C scientists

Forbes Contributor, Elaine Schattner, writes about several pieces of research that were presented at the recent Annual Meeting of the American Association for Cancer Research.  A physician herself, Schattner lays out the evidence that the drug olaparib has unexpected anti-tumor activity in ovarian and prostate cancers.  SU2C was proud to support the studies presented by Ursula Matulonis, MD, of Dana-Farber Cancer Institute and Joaquin Mateo, MD, of the Institute for Cancer Research in the U.K.

JOIN OUR COMMUNITY

Sign up to receive emails from Stand Up To Cancer.
   Please leave this field empty
Stand Up to Cancer

Thanks for signing up!
You will hear from us soon.